Azithromycin as a novel treatment for bronchiolitis obliterans syndrome

Nir Peled, David Shitrit, Daniele Bendayan, Mordechai R. Kramer

Research output: Contribution to journalReview articlepeer-review


Bronchiolitis obliterans syndrome (BOS) is one of the main causes of mortality after lung and bone marrow transplantation. Up to 75% of lung transplantation patients develop BOS within 5 years, whereas after bone marrow transplantation 14% of the patients develop the disease with 65% mortality within 3 years. Patients demonstrate gradual decrease in pulmonary functions with no significant anatomic/imagine findings. Therapeutic trials with high dose systemic corticosteroids, immune suppression and immunomodulation did not show any significant success. However, macrolides and especially azithromycin have recently been reported as highly efficient for BOS. This review summarizes information on the disease focusing on the clinical experience with azithromycin as a treatment for BOS.

Original languageEnglish
Pages (from-to)219-222
Number of pages4
Issue number3
StatePublished - Mar 2007


  • Azithromycin
  • Bone marrow transplantation (BMT)
  • Cystic fibrosis (CF)
  • Lung transplantation


Dive into the research topics of 'Azithromycin as a novel treatment for bronchiolitis obliterans syndrome'. Together they form a unique fingerprint.

Cite this